drugset / Trial / NCT01518920

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

NCT01518920

Phase 1 Completed 44 enrolled Biogen
RandomizedCrossoverTriple-blindTreatment

Summary

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

Timeline

Start
2011-12
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.27 mg Oral
Subject PESAMPATOR Small molecule 0.35 mg Oral